BakrisGL, AgarwalR, AnkerSD, et al.; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med, 2020; 383(23):2219–2229.
2.
PittB, FilippatosG, AgarwalR, et al.; FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med, 2021; 385(24):2252–2263.
3.
JoumaaJP, RaffoulA, SarkisC, et al.Mechanisms, biomarkers, and treatment approaches for diabetic kidney disease: Current insights and future perspectives. J Clin Med, 2025; 14(3):727.
4.
Sanz-GómezM, Manzano-ListaFJ, Vega-MartínE, et al.Finerenone protects against progression of kidney and cardiovascular damage in a model of type 1 diabetes through modulation of proinflammatory and osteogenic factors. Biomed Pharmacother, 2023; 168:115661.
5.
HeerspinkHJL, BirkenfeldAL, CherneyDZI, et al.Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial. Diabetes Res Clin Pract, 2023; 204:110908.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
